Reaffirmed: Allena Pharmaceuticals (ALNA) “Buy” Rating Reiterated at B. Riley FBR; $25 Target in Place

August 9, 2018 - By Margaret Guttierez

Allena Pharmaceuticals (ALNA) Rating Reaffirmed

In a research report revealed to clients and investors this morning, B. Riley FBR maintained their “Buy” rating on Allena Pharmaceuticals (ALNA) shares. The TP indicates a possible upside of 117.39 % from firm’s current stock price.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ratings Coverage

Among 4 analysts covering Allena Pharmaceuticals Inc (ALNA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Allena Pharmaceuticals Inc has $6100 highest and $22 lowest target. $33.80’s average target is 193.91% above currents $11.5 stock price. Allena Pharmaceuticals Inc had 10 analyst reports since March 9, 2018 according to SRatingsIntel. The stock has “Buy” rating by Wedbush on Wednesday, March 28. The firm has “Buy” rating given on Tuesday, May 22 by Wedbush. The stock of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has “Buy” rating given on Wednesday, August 8 by FBR Capital. FBR Capital maintained it with “Buy” rating and $23.5000 target in Tuesday, April 24 report. The company was maintained on Wednesday, June 20 by Wedbush. The firm has “Buy” rating given on Friday, March 9 by Wedbush. The stock of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has “Buy” rating given on Monday, April 2 by Roth Capital.

The stock decreased 1.71% or $0.2 during the last trading session, reaching $11.5. About 22,505 shares traded. Allena Pharmaceuticals, Inc. (ALNA) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to report earnings on August, 14. After $-0.38 actual earnings per share reported by Allena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.89 % negative EPS growth.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company has market cap of $238.65 million. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It currently has negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More recent Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) news were published by: Seekingalpha.com which released: “Allena Pharma’s mid-stage basket study of ALLN-177 in hyperoxaluria underway” on July 23, 2018. Also Nasdaq.com published the news titled: “Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update” on August 07, 2018. Globenewswire.com‘s news article titled: “Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference” with publication date: August 07, 2018 was also an interesting one.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.